MAYZENT

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Croatia, Cyprus, Estonia, Finland, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Spain, UK.

Active ingredients

The drug MAYZENT contains one active pharmaceutical ingredient (API):

1	Siponimod UNII RR6P8L282I - SIPONIMOD
	Siponimod is a sphingosine-1-phosphate (S1P) receptor modulator. By acting as a functional antagonist on S1P1 receptors on lymphocytes, siponimod prevents egress from lymph nodes. This reduces the recirculation of T cells into the central nervous system (CNS) to limit central inflammation. Siponimod is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease.
	Read more about Siponimod

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MAYZENT Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)
MAYZENT Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AE03		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AE Sphingosine-1-phosphate (S1P) receptor modulators
Discover more medicines within L04AE03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	12158X, 12160B, 12172P
CA	Health Products and Food Branch	02496429, 02496437
EE	Ravimiamet	1809873, 1809884, 1809895, 1836334, 1836345, 1836356, 1875810, 1875821
ES	Centro de información online de medicamentos de la AEMPS	1191414001, 1191414003
FI	Lääkealan turvallisuus- ja kehittämiskeskus	098363, 414921, 532526
GB	Medicines & Healthcare Products Regulatory Agency	380800, 380801, 380804
HK	Department of Health Drug Office	66875, 66876
IE	Health Products Regulatory Authority	89118, 89119, 89120
IL	מִשְׂרַד הַבְּרִיאוּת	8521, 8721, 8722
IT	Agenzia del Farmaco	048440010, 048440022, 048440034, 048440046, 048440059, 048440061, 048440073, 048440085
JP	医薬品医療機器総合機構	3999051F1024, 3999051F2020
LT	Valstybinė vaistų kontrolės tarnyba	1089279, 1089280, 1089281, 1089618, 1090109, 1090110
NL	Z-Index G-Standaard, PRK	202010, 202029
NZ	Medicines and Medical Devices Safety Authority	21327, 21328
PL	Rejestru Produktów Leczniczych	100432765, 100432771
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66696001, W66696002, W66696003, W66697001, W66697002, W66697003, W68730001, W68730002
US	FDA, National Drug Code	0078-0979, 0078-0986